Search jobs Cambridge Research Biochemicals signs distribution deal with Fluoroprobes, LLC
Cleveland, UK, 29th April 2021 / Sciad Newswire / Leading UK peptide and antibody producers, Cambridge Research Biochemicals (CRB) have today signed a new distribution agreement with Fluoroprobes, LLC (FPL) and Click Chemistry Tools (CCT) to add FPL and CCT’s generic fluorescent activated dyes and click chemistry enabled click-reactive dyes to their existing service portfolio. The distribution agreement grants CRB the rights to market and sell the generic and improved Alexa Fluor-based DISCOVERY® Dyes both as part of their custom services, and with their catalogue peptide (DISCOVERY® Peptides) and antibody (DISCOVERY® Antibodies) services in the UK and Europe.
Antibiotic Research UK launches £200,000 small research grants programme to tackle antibiotic resist pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.
Search jobs 18-Jan-2021 Antibiotic Research UK announces the appointment of Mr. Simon Dukes as Chair Designate of the Board of Trustees
York, UK, 18th January 2021 / Sciad Newswire / Antibiotic Research UK is delighted to announce the appointment of Mr. Simon Dukes as Chair Designate of its Board of Trustees.
Simon is currently in the news in his role as CEO of the Pharmaceutical Services Negotiating Committee (PSNC) where he is in negotiations with Government on the role of community pharmacies in rolling out the COVID-19 vaccination programme. Simon leads the PSNC committee, and is responsible and accountable for all operational dimensions of the organisation. These include the planning and shaping of NHS services provided by the network of over 11,000 community pharmacies in England, as well as negotiating funding from HM Government. Prior to this Simon was Chief Executive of the UK’s Fraud Prevention Service, Cifas. There,
Search jobs NanoSyrinx strengthens board with appointment of Dr Jane Dancer as Non-Executive Director
Coventry, UK, 10th December 2020 / Sciad Newswire / NanoSyrinx announces the appointment of Dr Jane Dancer to its Board as Non-Executive Director. NanoSyrinx is an early-stage biotechnology company using synthetic biology approaches to develop a completely novel platform for targeted drug delivery of therapeutic proteins and peptides, to the interiors of cells. Dr Dancer has over 30 years’ experience in business development across biotech, pharma and agrochemicals and her experience will help to drive NanoSyrinx’s ongoing fundraising activities and ambitious growth plans.
Dr Dancer is a highly experienced business leader with previous roles including Chief Business Officer at F-star, Vice President of Business Development at Cellzome and Director, Business Development at MedImmune Ltd (formerly Cambridge Antibody Technology (CAT)). Jane holds an MA